Corvus Pharmaceuticals(CRVS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2025 totaled $9.9 million, up from $6 million in Q4 2024, with full-year R&D expenses reaching $33.7 million compared to $19.4 million in 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel costs [4] - Net loss for Q4 2025 was $12.3 million, slightly higher than the net loss of $12.1 million in Q4 2024, with total stock compensation expense increasing to $1.6 million from $0.8 million in the same period [5] - As of December 31, 2025, cash equivalents and marketable securities totaled $56.8 million, up from $52 million at the end of 2024, with pro forma cash including net proceeds from a public offering amounting to approximately $246 million, extending the cash runway into Q2 2028 [6] Business Line Data and Key Metrics Changes - Significant progress was made in the development of soquelitinib, with ongoing enrollment in the phase 3 trial for peripheral T-cell lymphoma (PTCL) and a recently initiated phase 2 trial for atopic dermatitis [9] - The phase 1 trial results for soquelitinib in atopic dermatitis showed a mean percent reduction in EASI of 72% compared to 40% for placebo, with 75% of patients achieving EASI 75 [12] Market Data and Key Metrics Changes - The company is entering 2026 with strong investor interest, highlighted by a $200 million financing, reflecting confidence in the potential of soquelitinib and ITK inhibition [8] - The phase 1 trial data presented at the ASH annual meeting indicated that soquelitinib could be a leading therapy for atopic dermatitis and other inflammatory diseases, with a favorable comparison to existing treatments [25] Company Strategy and Development Direction - The company plans to expand its clinical trials for soquelitinib into mid-stage trials for other inflammatory diseases such as hidradenitis suppurativa and asthma later in the year [9] - The strategy focuses on leveraging the unique mechanism of action of soquelitinib to address multiple inflammatory diseases, with ongoing research into its safety and efficacy [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of soquelitinib across various indications, emphasizing the drug's unique properties and the promising clinical data supporting its use [27] - The company is optimistic about the upcoming data readouts from ongoing trials, which are expected to provide further insights into the drug's efficacy and safety [33] Other Important Information - The company is collaborating with Angel Pharmaceuticals for a phase 1b/2 trial in China, which is expected to provide additional data on soquelitinib's efficacy in atopic dermatitis [21] - The phase 2 trial for atopic dermatitis is set to enroll 200 patients, with results anticipated in mid-2027 [24] Q&A Session Summary Question: Regarding the upcoming data readouts for PTCL and the China study - Management indicated that initial data from Angel Pharmaceuticals' trial will be available later this year, with further data expected in 2027 [31][33] Question: Expectations for the SID meeting presentation - Management highlighted that the presentation will focus on durability and new biomarkers related to soquelitinib's mechanism of action [37] Question: Insights on the phase 2 trial in hidradenitis suppurativa - Management stated that they expect efficacy to be comparable or better than existing biologics, with ongoing assessments to determine optimal dosing [40] Question: Comments on the ALPS trial and its implications - Management noted that while results from the ALPS trial are promising, they do not directly predict outcomes for other autoimmune diseases [68] Question: Enrollment dynamics in the PTCL trial - Management confirmed that the trial is progressing well, with patients being randomized to receive either soquelitinib or standard care options [72][75] Question: Durability of response in the phase 2 trial - Management confirmed that the phase 2 trial includes a follow-up period to assess durability, although the primary endpoint remains the EASI score at 12 weeks [93]